ブラキセラピー装置の世界市場-2025～2033年

ブラキセラピー装置の世界市場は、2024年に10億2,410万米ドルに達し、2033年には19億270万米ドルに達すると予測され、予測期間2025～2033年のCAGRは7.2%で成長すると予測されています。

ブラキセラピー装置は、放射性線源を腫瘍の内部またはごく近傍に直接設置する内部放射線治療の一形態であるブラキセラピーに使用される特殊な医療装置を指します。この装置は、周囲の健康な組織への被ばくを最小限に抑えながら、腫瘍に高線量の放射線を照射するため、特に限局したがんに対して的を絞った効果的な治療となります。ブラキセラピーは、さまざまな種類のがんに対して効果的で的を絞った治療法を提供します。治療精度の高さ、副作用の軽減、治療期間の短縮により、局所がん患者にとって貴重な選択肢となっています。

世界のブラキセラピー装置市場は、がんの有病率の増加、技術の進歩、低侵襲治療への嗜好の高まりなどの要因によって、大きな成長を遂げています。例えば、International Journal of Radiation Oncology, Biology, Physicsが実施した調査によると、8,500人の女性のうち36％がEBRTのみを受け、64％がEBRTに加えてブラキセラピーを受けています。2003年から2004年にかけて急落した後（2003年の最低率は44％）、ブラキセラピーの使用率は着実に増加し、特に2018年から2020年にかけては76％に達しています。

市場力学：

促進要因と抑制要因

がん有病率の上昇

がんの有病率の上昇がブラキセラピー装置市場の成長を大きく牽引しており、予測期間中も市場を牽引すると予測されます。ブラキセラピーは、前立腺がん、乳がん、子宮頸がん、皮膚がんなどの限局がんに特に有効です。この方法は、高線量の放射線を腫瘍に直接照射するため、周囲の健康な組織へのダメージを最小限に抑えることができます。例えば、国立衛生研究所によれば、世界における主な死亡原因のひとつはがんです。世界全体では、2022年には約2,000万人の患者が新たに発生しました。2040年には2,990万人が新たにがんにかかると予測されています。

ブラキセラピーは、限局性前立腺がん、特に早期腫瘍の治療に適していると考えられています。膀胱や直腸などの近傍臓器への損傷を最小限に抑えながら高線量を照射することができるため、この増加する患者群にとって非常に効果的な治療法となっています。例えば、米国がん協会の推計によると、米国では2024年に約299,010人の前立腺がん患者が新たに発生します。

ブラキセラピーに伴う高コスト

ブラキセラピーに伴う高コストは、ブラキセラピー装置市場の成長を妨げる重要な要因です。装置への初期投資、継続的なメンテナンス、放射性物質のコストなど、このコストにはいくつかの側面があり、特にヘルスケア予算が限られている地域では、普及の障壁となっています。例えば、HOSPIDIOによると、インドにおけるブラキセラピー費用は2,000ドルから4,500ドルで、これは約16万から37万インドルピーに相当します。

アフターローダー、アプリケーター、治療計画システムなどのブラキセラピー装置の購入費用は、数十万米ドルから数百万米ドルに及びます。例えば、最新のブラキセラピーで一般的に使用されている高線量率（HDR）アフターローダーは、機種や技術によっては高額になることもあります。

例えば、米国国立衛生研究所（NIH）によると、HDRアフターローダーは2020年には平均で20万米ドルから35万米ドルの費用がかかり、年間の定期点検と線源交換費用は20,000米ドルをはるかに超えるといいます。

目次

第1章 市場イントロダクションと範囲

• 報告書の目的
• 調査範囲と定義
• 調査範囲

第2章 エグゼクティブの洞察と重要なポイント

• 市場のハイライトと戦略的ポイント
• 主な動向と将来の予測
• 投与量タイプ別スニペット
• 製品タイプ別スニペット
• 技術タイプ別スニペット
• 用途別スニペット
• エンドユーザー別スニペット
• 地域別スニペット

第3章 市場力学

• 影響要因
  • 促進要因
    • がん罹患率の上昇
  • 抑制要因
    • ブラキセラピーの高額な費用
  • 機会
  • 影響分析

第4章 戦略的洞察と業界展望

• 市場のリーダーと先駆者
  • 新たな先駆者と著名なプレーヤー
  • 最大の売上を誇るブランドを確立したリーダー
  • 確立された製品を持つ市場リーダー
• 新興スタートアップ企業と主要イノベーター
• CXOの視点
• 最新の開発とブレークスルー
• ケーススタディ/進行中の調査
• 規制と償還の情勢
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ
• ポーターのファイブフォース分析
• サプライチェーン分析
• 特許分析
• SWOT分析
• アンメットニーズとギャップ
• 市場参入と拡大のための推奨戦略
• シナリオ分析ベストケース、ベースケース、ワーストケースの予測
• 価格分析と価格市場力学

第5章 ブラキセラピー装置市場、投与量タイプ別

• 高線量率（HDR）ブラキセラピー
• 低線量率（LDR）ブラキセラピー

第6章 ブラキセラピー装置市場、製品タイプ別

• シード
• ブラキセラピーアプリケーター
• ブラキセラピーアフターローダー
• 電子ブラキセラピー

第7章 ブラキセラピー装置市場、技術タイプ別

• 超音波ガイド下ブラキセラピー
• 磁気共鳴画像（MRI）ガイド下ブラキセラピー
• コンピュータ断層撮影（CT）ガイド下ブラキセラピー
• 陽電子放出断層撮影（PET）ガイド下ブラキセラピー
• その他

第8章 ブラキセラピー装置市場、用途別

• 前立腺がん
• 皮膚がん
• 婦人科がん
• 乳がん
• 子宮頸がん
• その他

第9章 ブラキセラピー装置市場、エンドユーザー別

• 病院
• 診断センター
• 放射線治療センター
• 外来手術センター
• その他

第10章 ブラキセラピー装置市場、地域別市場分析と成長機会

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第11章 競合情勢と市場ポジショニング

• 競合状況の概要と主要な市場プレーヤー
• 市場シェア分析とポジショニングマトリックス
• 戦略的パートナーシップ、合併、買収
• 製品ポートフォリオとイノベーションにおける主な発展
• 企業ベンチマーク

第12章 企業プロファイル

• Elekta AB
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
  • SWOT分析
• Varian Medical Systems, Inc.
• Eckert & Ziegler
• Theragenics Corporation
• Becton, Dickinson, and Company
• BEBIG Medical
• Sun Nuclear Corporation
• CIVCO Medical Solutions

第13章 仮定と調査手法

• データ収集方法
• データの三角測量
• 予測技術
• データの検証と検証

第14章 付録

The global brachytherapy devices market reached US$ 1,024.1 million in 2024 and is expected to reach US$ 1,902.7 million by 2033, growing at a CAGR of 7.2% during the forecast period 2025-2033.

Brachytherapy devices refer to specialized medical devices used in brachytherapy, a form of internal radiation therapy where radioactive sources are placed directly inside or very close to a tumor. The devices deliver a high dose of radiation to the tumor while minimizing exposure to surrounding healthy tissues, making it a targeted and effective treatment, especially for localized cancers. Brachytherapy offering an effective and targeted treatment method for various types of cancer. The precision, reduced side effects and shorter treatment times make it a valuable option for patients with localized cancers.

The global brachytherapy devices market is experiencing significant growth, driven by factors such as the increasing prevalence of cancer, technological advancements and a rising preference for minimally invasive treatments. For instance, according to the study conducted by International Journal of Radiation Oncology, Biology, Physics, of the 8500 women, 36% underwent EBRT alone, and 64% received brachytherapy in addition to EBRT. After a steep fall in 2003-2004 (with the lowest rate of 44% in 2003), the brachytherapy usage rate steadily increased, particularly from 2018 to 2020 (76%).

Market Dynamics: Drivers & Restraints

Rising prevalence of cancer

The rising prevalence of cancer is significantly driving the growth of the brachytherapy devices market and is expected to drive the market over the forecast period. Brachytherapy is particularly effective for localized cancers like prostate, breast, cervical and skin cancers. The method delivers high doses of radiation directly to the tumor, minimizing damage to surrounding healthy tissue, which is crucial for patients suffering from these increasing cancer cases. For instance, according to the National Institute of Health, one of the main causes of mortality in the globe is cancer. Globally, there were about 20 million new cases in 2022. It is anticipated that there will be 29.9 million new cancer cases year by 2040.

Brachytherapy is considered a preferred treatment for localized prostate cancer, particularly in early-stage tumors. Its ability to provide a high radiation dose with minimal damage to nearby organs, such as the bladder and rectum, makes it a highly effective treatment method for this growing patient population. For instance, according to the American Cancer Society's estimates in the United States in 2024, about 299,010 new cases of prostate cancer.

High cost associated with brachytherapy

The high cost associated with brachytherapy is a significant factor that hampers the growth of the brachytherapy devices market. Several aspects of this cost, including the initial investment in equipment, ongoing maintenance and the cost of radioactive materials, present barriers to widespread adoption, particularly in regions with limited healthcare budgets. For instance, according to the HOSPIDIO, brachytherapy cost in India can range from $2000 to $4500, which is equivalent to approximately 1,60,000 to 3,70,000 Indian rupees.

The cost of purchasing brachytherapy equipment such as afterloaders, applicators, and treatment planning systems can range from hundreds of thousands to millions of dollars. For instance, a high-dose rate (HDR) afterloader, which is commonly used in modern brachytherapy procedures, can cost high depending on the model and technology.

For instance, according to the National Institute of Health (NIH), an HDR afterloader will cost between USD 200,000 and USD 350,000 on average in 2020, with recurring yearly servicing and source exchange expenses of well over USD 20,000.

Segment Analysis

The global brachytherapy devices market is segmented based on dosage type, product type, technique type, application, end-user and region.

Dosage Type:

The High-Dose Rate (HDR) brachytherapy segment is expected to dominate the brachytherapy devices market share

High-Dose Rate (HDR) brachytherapy allows for the delivery of a high dose of radiation in a short period, enabling precise targeting of the tumor. This results in better tumor control with minimal damage to surrounding healthy tissue. HDR brachytherapy sessions are typically much shorter than those of Low Dose Rate (LDR), which makes it more convenient for both patients and healthcare providers. HDR treatments can be completed within a few minutes per session, whereas LDR treatments can span several days.

High-Dose Rate (HDR) brachytherapy is widely used in the treatment of localized prostate cancer. In prostate cancer treatment, HDR has shown comparable, if not superior, outcomes to LDR in terms of tumor control, with a shorter treatment duration.

For instance, in July 2024, GE HealthCare's MIM Software introduced MIM Symphony HDR Prostate to support high dose-rate (HDR) brachytherapy. By offering direct tumor visualization from magnetic resonance imaging (MRI) images during live ultrasound operations for HDR prostate treatments, this novel technology seeks to boost clinician confidence and contribute to better patient outcomes. By providing MRI guiding and correcting MRI alignment during HDR prostate treatments, MIM Symphony HDR Prostate distinguishes itself in the industry.

Geographical Analysis

North America is expected to hold a significant position in the brachytherapy devices market share

According to the American Cancer Society, approximately 1.9 million new cancer cases were expected to be diagnosed in the United States in 2023, with prostate, breast, and gynecological cancers being some of the most common. This rising cancer burden creates a growing demand for effective, targeted treatments like brachytherapy.

The U.S. has one of the highest incidences of prostate cancer globally, with an estimated 1 in 8 men being diagnosed. Brachytherapy, particularly HDR brachytherapy, is a leading treatment choice for localized prostate cancer, contributing significantly to the growth of the brachytherapy devices market.

North America has seen significant adoption of high-dose rate (HDR) brachytherapy devices, which offer superior precision and faster treatment times. The use of real-time imaging, automated afterloaders, and improved treatment planning systems are particularly prevalent in this region, enhancing the effectiveness of brachytherapy treatments.

Companies like Varian Medical Systems, Elekta and other emerging players are based in North America and lead the development of next-generation brachytherapy devices. These innovations ensure that North American healthcare providers are equipped with the most advanced technologies available.

Asia-Pacific is growing at the fastest pace in the brachytherapy devices market

The APAC region has seen a significant rise in cancer cases due to factors such as population growth, aging populations, urbanization, and lifestyle changes. According to the International Agency for Research on Cancer (IARC), Asia accounted for 47% of the global cancer burden in 2020. Countries like China, India, and Japan have some of the highest cancer rates globally. This surge in cancer cases is driving demand for effective treatments like brachytherapy.

Governments in APAC countries are increasingly investing in healthcare infrastructure, including cancer treatment facilities. This investment is critical for expanding access to advanced therapies like brachytherapy. For instance, the Indian government's focus on improving healthcare access and cancer treatment capabilities has resulted in greater availability of brachytherapy devices in the country.

As patients in the APAC region increasingly demand minimally invasive treatment options, the adoption of brachytherapy continues to rise. Its ability to deliver targeted radiation with reduced risk of side effects and shorter recovery times makes it an attractive treatment option. For instance, in South Korea, patients are becoming more inclined toward advanced cancer therapies like HDR brachytherapy, which requires fewer hospital visits and allows for faster recovery compared to traditional external beam radiation therapy.

Competitive Landscape

The major global players in the brachytherapy devices market include Elekta AB, Varian Medical Systems, Inc., Eckert & Ziegler, Theragenics Corporation, Becton, Dickinson, and Company, BEBIG Medical, Sun Nuclear Corporation, CIVCO Medical Solutions and among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global brachytherapy devices market report delivers a detailed analysis with 72 key tables, more than 77 visually impactful figures, and 169 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

• 1.1. Objectives of the Report
• 1.2. Report Coverage & Definitions
• 1.3. Report Scope

2. Executive Insights and Key Takeaways

• 2.1. Market Highlights and Strategic Takeaways
• 2.2. Key Trends and Future Projections
• 2.3. Snippet by Dosage Type
• 2.4. Snippet by Product Type
• 2.5. Snippet by Technique Type
• 2.6. Snippet by Application
• 2.7. Snippet by End-User
• 2.8. Snippet by Region

3. Dynamics

• 3.1. Impacting Factors
  • 3.1.1. Drivers
    • 3.1.1.1. Rising Prevalence of Cancer
  • 3.1.2. Restraints
    • 3.1.2.1. High Cost of Brachytherapy
  • 3.1.3. Opportunity
  • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

• 4.1. Market Leaders and Pioneers
  • 4.1.1. Emerging Pioneers and Prominent Players
  • 4.1.2. Established leaders with largest selling Brand
  • 4.1.3. Market leaders with established Product
• 4.2. Emerging Startups and Key Innovators
• 4.3. CXO Perspectives
• 4.4. Latest Developments and Breakthroughs
• 4.5. Case Studies/Ongoing Research
• 4.6. Regulatory and Reimbursement Landscape
  • 4.6.1. North America
  • 4.6.2. Europe
  • 4.6.3. Asia Pacific
  • 4.6.4. Latin America
  • 4.6.5. Middle East & Africa
• 4.7. Porter's Five Force Analysis
• 4.8. Supply Chain Analysis
• 4.9. Patent Analysis
• 4.10. SWOT Analysis
• 4.11. Unmet Needs and Gaps
• 4.12. Recommended Strategies for Market Entry and Expansion
• 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 4.14. Pricing Analysis and Price Dynamics

5. Brachytherapy Devices Market, By Dosage Type

• 5.1. Introduction
  • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
  • 5.1.2. Market Attractiveness Index, By Dosage Type
• 5.2. High-Dose Rate (HDR) Brachytherapy*
  • 5.2.1. Introduction
  • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 5.3. Low-Dose Rate (LDR) Brachytherapy

6. Brachytherapy Devices Market, By Product Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 6.1.2. Market Attractiveness Index, By Product Type
• 6.2. Seeds*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Brachytherapy Applicators
• 6.4. Brachytherapy Afterloaders
• 6.5. Electronic Brachytherapy

7. Brachytherapy Devices Market, By Technique Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique Type
  • 7.1.2. Market Attractiveness Index, By Technique Type
• 7.2. Ultrasound-Guided Brachytherapy*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Magnetic Resonance Imaging (MRI)-Guided Brachytherapy
• 7.4. Computed Tomography (CT)-Guided Brachytherapy
• 7.5. Positron Emission Tomography (PET)-Guided Brachytherapy
• 7.6. Others

8. Brachytherapy Devices Market, By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Prostate Cancer*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Skin Cancer
• 8.4. Gynecological Cancer
• 8.5. Breast Cancer
• 8.6. Cervical Cancer
• 8.7. Others

9. Brachytherapy Devices Market, By End-User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.1.2. Market Attractiveness Index, By End-User
• 9.2. Hospitals*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Diagnostic Centers
• 9.4. Radiotherapy Centers
• 9.5. Ambulatory Surgical Centers
• 9.6. Others

10. Brachytherapy Devices Market, By Regional Market Analysis and Growth Opportunities

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique Type
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.8.1. U.S.
    • 10.2.8.2. Canada
    • 10.2.8.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique Type
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.8.1. Germany
    • 10.3.8.2. U.K.
    • 10.3.8.3. France
    • 10.3.8.4. Spain
    • 10.3.8.5. Italy
    • 10.3.8.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique Type
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.8.1. Brazil
    • 10.4.8.2. Argentina
    • 10.4.8.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique Type
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.8.1. China
    • 10.5.8.2. India
    • 10.5.8.3. Japan
    • 10.5.8.4. South Korea
    • 10.5.8.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique Type
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape and Market Positioning

• 11.1. Competitive Overview and Key Market Players
• 11.2. Market Share Analysis and Positioning Matrix
• 11.3. Strategic Partnerships, Mergers & Acquisitions
• 11.4. Key Developments in Product Portfolios and Innovations
• 11.5. Company Benchmarking

12. Company Profiles

• 12.1. Elekta AB*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
  • 12.1.5. SWOT Analysis
• 12.2. Varian Medical Systems, Inc.
• 12.3. Eckert & Ziegler
• 12.4. Theragenics Corporation
• 12.5. Becton, Dickinson, and Company
• 12.6. BEBIG Medical
• 12.7. Sun Nuclear Corporation
• 12.8. CIVCO Medical Solutions

LIST NOT EXHAUSTIVE

13. Assumption and Research Methodology

• 13.1. Data Collection Methods
• 13.2. Data Triangulation
• 13.3. Forecasting Techniques
• 13.4. Data Verification and Validation

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us